Key result
Temporary blockade of IFN-γ using anti-IFN-γ antibody R46-A2 ameliorated doxorubicin-induced cardiac dysfunction in mice without compromising the anti-tumor effect of doxorubicin.
Why the study?
Doxorubicin causes severe cardiotoxicity, and following findings that IFN-γ is necessary for acute toxicity, whether IFN-γ blockade prevents chronic cardiotoxicity remained unknown.
Does temporary blockade of IFN-γ with R46-A2 prevent or ameliorate doxorubicin-induced cardiotoxicity in mice without affecting anti-tumor efficacy?
Does temporary blockade of IFN-γ with R46-A2 prevent or ameliorate doxorubicin-induced cardiotoxicity in mice without affecting anti-tumor efficacy?
Temporary blockade of IFN-γ protects against doxorubicin-induced cardiotoxicity in a mouse model without compromising anti-tumor efficacy.
Should not yet change practice; leaves open whether temporary IFN-γ blockade prevents chronic DIC in patients.
Doxorubicin (DOX) is commonly used as an anti-cancer agent. However, its severe cardiotoxicity often makes it life threatening even long after DOX therapy during childhood. We recently reported interferon-γ (IFN-γ) necessary for DOX-induced acute cardiotoxicity in a p38 dependent way and, asked here for the potential of IFN-γ blockade to prevent DOX-induced chronic cardiotoxicity during tumor therapy. In our model system, mice without or with growing tumors repeatedly received DOX treatment. Simultaneous injection of anti-IFN-γ antibody R46-A2 with DOX to block IFN-γ signal efficiently protected the cardiac function of DOX treated recipients. Importantly, a single late injection of R46-A2 after DOX exposure also ameliorated DOX induced cardiac dysfunction in tumor-bearing mice. The anti-IFN-γ treatment did not affect the DOX-mediated tumor suppression effect and it left the main cellular immune response intact. Therefore, temporary blockade of IFN-γ may represent a novel strategy to ameliorate established DOX induced cardiotoxicity (DIC) or prevent its development in tumor therapy.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2020) studied Doxorubicin-induced cardiotoxicity. Anti-IFN-γ antibody R46-A2 vs. Doxorubicin treatment alone was evaluated on Cardiac function. Temporary blockade of IFN-γ using anti-IFN-γ antibody R46-A2 ameliorated doxorubicin-induced cardiac dysfunction in mice without compromising the anti-tumor effect of doxorubicin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: